Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

HISTORICAL FACTS: Arcturus therapeutics s return on capital employed insights - Caught on Camera

According to Benzinga Pro data, during Q4, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $5.79 million. Earnings were up 28.51%, but Arcturus Therapeutics still reported an overall loss of $38.66 million. In Q3, Arcturus Therapeutics brought in $2.44 million in sales but lost $54.08 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.